Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alkermes, Inc.
Three active treatment groups and a placebo group are planned. Randomization will be sequential by dose level across the sites with placebo assignments randomly inserted. Each subject's participation will be approximately 8 months, including screening, treatment period, and a 3-month follow-up period.
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of chronic schizophrenia that is clinically stable
Body mass index (BMI) between 18.5 and 35.0 kg/m2, inclusive
Stable antipsychotic medication regimen for \>/= 2 months before Screening
Be willing and able to be confined to an inpatient clinical research unit for a total of 37 days during the course of the study
You may not be if
Aripiprazole used within 30 days before Screening
History of intolerance of or allergy or hypersensitivity to aripiprazole, its excipients, other antipsychotic agents, or INTRALIPID (including peanuts, soy, egg, or glycerol)
Current diagnosis of an Axis I disorder other than schizophrenia
History of seizure disorder or any condition associated with seizures
History of neuroleptic malignant syndrome (NMS)
Positive test result for HIV, hepatitis B surface antigen, or anti-hepatitis C antibodies
Received medication by IM injection within 30 days before Screening
Monoamine oxidase inhibitors (eg, phenelzine, tranylcypromine, selegiline) used within 30 days before Screening
DSM-IV-TR diagnosis of alcohol or substance dependence, with the exception of nicotine or caffeine dependence within 12 months before Screening
Donation of blood or blood components within 4 weeks before Screening
